Evaluation of Anti-Amyloid Compounds

A testing and option agreement has been announced by Neurochem, Inc. (St. Laurent, Canada) that will allow the company to evaluate a new class of compounds with potential anti-amyloid activity for the treatment of Alzheimer's disease.

The compounds were developed by the University of North Carolina at Chapel Hill (USA) and Georgia State University (City, USA). Immtech International, Inc. (Vernon Hills, IL, USA) has a worldwide license to the technology. Neurochem will evaluate the Immtech compounds through the use of laboratory and animal models of amyloid disease. After the initial option period, the two companies may enter into a licensing agreement that would include milestone payments for compounds identified with significant anti-amyloid activity by Neurochem's researchers.

"Our preliminary discovery work has indicated that this family of compounds has a good anti-fibrillogenic profile, which is very complementary to our comprehensive Alzheimer's disease and central nervous system programs,” said Dr. Louis R. Lamontagne, CEO and president of Neurochem. "Using our in-house expertise in laboratory and animal models to develop these compounds, we see the potential for expanded pharmaceutical applications in all our therapeutic target areas.”




Related Links:
Neurochem
Immtech